Wiggle Butt Academy Welcomes Rhea Northcut, CPDT-KA, CSAT, FDM — A Certified Expert in Separation Anxiety Training
Wiggle Butt Academy, a leader in science-based, positive reinforcement training, is proud to announce the addition of Rhea Northcut to the team.
'Separation Anxiety can be heartbreaking for both dogs and their humans. It's one of the leading causes of behavior-related surrender.'— Nicole Kohanski
TX, UNITED STATES, May 12, 2025 / EINPresswire.com / -- Wiggle Butt Academy, a leader in science-based, fear-free dog training in the DFW Metroplex, is proud to announce the addition of Rhea Northcut, CPDT-KA, CSAT, FDM to its expert team. Rhea joins Wiggle Butt Academy with over a decade of experience and a deep specialization in one of the most challenging behavior issues pet guardians face today: Separation Anxiety.
Rhea holds the prestigious Certified Separation Anxiety Trainer (CSAT) credential—an advanced certification achieved through a rigorous training program requiring hundreds of hours of instruction. She is one of two CSATs on the Wiggle Butt Academy team, joining fellow specialist Nicole Kohanski. Through a structured and evidence-based protocol, Rhea works virtually with clients across the globe to help dogs overcome the panic and distress caused by being left alone.
'Separation Anxiety can be heartbreaking for both dogs and their humans. It's one of the leading causes of behavior-related surrender,' says Nicole Kohanksi, Founder of Wiggle Butt Academy. 'Rhea's CSAT certification allows us to expand our reach and support families not just locally, but around the world.'
In addition to her CSAT designation, Rhea is also a Certified Professional Dog Trainer – Knowledge Assessed (CPDT-KA) and a Family Dog Mediator (FDM) through Kim Brophy's groundbreaking L.E.G.S. Applied Ethology model. She earned her Bachelor of Arts in Psychology from Texas Tech University, where she first discovered her passion for animal behavior. After initially pursuing a Master's in Counseling, Rhea shifted her focus to dog training full-time, recognizing her true calling was helping dogs—and their people—understand each other.
Rhea's training background spans shelter work, boarding facilities, private in-home lessons, sport and manners training, and remote coaching. Her approach blends academic knowledge, behavioral science, and heartfelt compassion. When not training, she enjoys time with her husband, daughters, and their Icelandic Sheepdog, Lizzie.
Rhea is now accepting virtual separation anxiety clients worldwide, as well as behavior and training clients virtually. To learn more about Wiggle Butt Academy's Separation Anxiety Program or to book a consultation with Rhea, visit www.wigglebuttacademy.com.
Nicole Kohanski, MBA, CTC, CDBC, CBCC-KA, CSAT
Wiggle Butt Academy LLC
+1 214-210-2695
email us here
Visit us on social media:
Instagram
Facebook
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Suspected case of Measles under investigation in Lee County, Alabama
LEE COUNTY, Ala. (WRBL) — The Alabama Department of Public Health (ADPH) is investigating a suspected case of measles in Lee County involving an unvaccinated individual who was not yet eligible to receive the vaccine. The case is currently under review as part of ADPH's standard communicable disease response. Health officials say while the individual is confirmed to be unvaccinated, they were too young to have received the measles, mumps, and rubella (MMR) vaccine. The ADPH is now working closely with local medical providers to identify any other unvaccinated individuals who may need the MMR vaccine as a precaution. 'At this time, given that most eligible Alabamians are vaccinated against measles, the risk for an outbreak remains low,' ADPH officials said in a statement. 'However, some individuals will need to be vaccinated as part of this ongoing investigation.' Measles is a highly contagious virus that spreads through coughing, sneezing, and close contact. In rare but serious cases, it can lead to pneumonia, brain swelling, and even death — particularly in young children, the immunocompromised, and unvaccinated populations. 'Measles vaccine is safe and highly effective in producing lifelong immunity against this potentially deadly disease,' said Dr. Karen Landers, ADPH's Chief Medical Officer and a pediatrician. 'Our citizens can protect themselves and others by ensuring that all eligible persons are vaccinated.' ADPH says anyone who may have been exposed is being contacted directly by health officials or their healthcare providers. Due to patient privacy laws and HIPAA regulations, no additional personal information about the suspected case is being released at this time. For more information on measles symptoms, vaccine eligibility, and how to protect yourself, visit: Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Shelter calls on KC community amidst nationwide mental illness surge
KANSAS CITY, Mo. — Mental health issues are on the rise across the United States, according to one Kansas City shelter. They say it's causing more people to experience homelessness, especially in Kansas City. A new report from Citygate Network shows that 31% of Shelter KC guests were unhoused for the first time. That same report showed that 62% of those people reported that they've struggled with mental illness, which is well above the 47% national average. 'I've seen the demographics get younger,' said James Kohoutek, the Associate Director at Shelter KC. 'I've seen the amount of first-time homelessness increase as well as chronic homelessness. So, it's a rough situation we have.' Kansas City police stop potential sideshow during First Friday; enforcement continues Kohoutek shared research that shows limited access to health care, family trauma and financial strain are all contributing factors to mental illness. According to him, many just need a safe space and the right resources to make progress. 'Someone who sits off to the side away from the group, and then they start to sit more towards the group, and then they start to participate in the group discussion and the group classes,' he said, speaking on the progress he's seen in some cases. 'They start to engage in mental health services, they engage with their recovery coach or counselor. And you just see them come alive in a beautiful way.' Now, the shelter is calling on the KC community to get involved to break the cycle. Whether it's through volunteering or simply learning more about the crisis, Shelter KC believes it'll take everyone to make lasting change. 'We all need people in our lives to help us move forward, whether you're on the streets or standing behind a news camera. We all need that healthy support,' Kohoutek echoed. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
